Early Immunochemotherapy Timing Improves Survival in Advanced Lung Cancer
A Phase 3 trial shows administering immunochemotherapy before 3:00 PM improves survival outcomes in advanced NSCLC. Early treatment resulted in 11.3 months progression-free survival versus 5.7 months for late treatment, and 28.0 months overall survival versus 16.8 months. The findings suggest treatment timing is a modifiable factor that can enhance efficacy without additional cost.
Early time-of-day infusion of immunochemotherapy is associated with significantly improved progression-free survival and overall survival in patients with advanced non-small cell lung cancer, according to findings from a randomized Phase 3 trial. The LungTIME C01 trial demonstrated that administering immunotherapy before 3:00 PM nearly doubled progression-free survival and extended overall survival by more than 11 months compared to later administration.
The Phase 3 LungTIME C01 trial enrolled 210 patients with treatment-naive stage IIIC to IV non-small cell lung cancer lacking driver mutations. Participants were randomly assigned in a 1:1 ratio to receive the first four cycles of an anti-programmed death receptor-1 agent either before or after 15:00 hours, defining early and late time-of-day groups respectively. After a median follow-up of 28.7 months, median progression-free survival was 11.3 months in the early group versus 5.7 months in the late group, corresponding to a hazard ratio of 0.40 for earlier disease progression.
Median overall survival also favored early immunochemotherapy: 28.0 months in the early group versus 16.8 months in the late group, with a hazard ratio of 0.42 for earlier death. Treatment-related adverse events were consistent with the established safety profile, and no new safety signals were observed. The two groups had no significant differences in immune-related adverse events.
Immunological analyses demonstrated divergent circulating CD8+ T-cell dynamics over the first four cycles. Morning circulating CD8+ T-cells increased in the early group but declined in the late group. Furthermore, the ratio of activated (CD38+ HLA-DR+) versus exhausted (TIM-3+ PD-1+) CD8+ T-cells was higher in the early group compared with the late group. These data suggest enhanced antitumor CD8+ T-cell characteristics with early immunochemotherapy.
These findings have important implications for the routine clinical use of immunochemotherapy, offering a simple and cost-neutral strategy that can be readily implemented without imposing additional financial burden on the healthcare system. The prospective evidence from this trial supports the consideration of treatment timing as a modifiable factor in optimizing immunochemotherapy efficacy.